Statins accelerate the onset of collagen type II-induced arthritis in mice

Arthritis Research and Therapy

Volumn 14, Issue 2, 2012, Pages

  Vandebriel, Rob J ^a   De Jong, Hilda J I ^a,b,c   Gremmer, Eric R ^a   Klungel, Olaf H ^c   Tervaert, Jan Willem C ^d   Slob, Wout ^a   Van Der Laan, Jan Willem ^e   Van Loveren, Henk ^a,b  

^a NATIONAL INSTITUTE FOR PUBLIC HEALTH AND THE ENVIRONMENT   (Netherlands)

^b MAASTRICHT UNIVERSITY   (Netherlands)

^c UTRECHT UNIVERSITY   (Netherlands)

^d MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

^e MEDICINES EVALUATION BOARD   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ATORVASTATIN; COLLAGEN ANTIBODY; COLLAGEN TYPE 2; GAMMA INTERFERON; INTERLEUKIN 17; INTERLEUKIN 2; PRAVASTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY PRODUCTION; ARTICLE; AUTOIMMUNITY; CONTROLLED STUDY; CYTOKINE PRODUCTION; DRUG EFFECT; IMMUNOMODULATION; LYMPH NODE; MALE; MOUSE; NONHUMAN; RHEUMATOID ARTHRITIS; SPLEEN CELL; ANIMAL; ARTHRITIS; CATTLE; CHEMICALLY INDUCED DISORDER; DBA MOUSE; IMMUNOLOGY; PATHOLOGY;

ANIMALS; ARTHRITIS, EXPERIMENTAL; CATTLE; COLLAGEN TYPE II; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MALE; MICE; MICE, INBRED DBA;

EID: 84860116947     PISSN: 14786354     EISSN: 14786362     Source Type: Journal    
DOI: 10.1186/ar3814     Document Type: Article

References (42)

1. Baigent C, Keech A, Kearney PM, Blackwell L, Buck G, Pollicino C, Kirby A, Sourjina T, Peto R, Collins R, Simes R, . Cholesterol Treatment Trialists' Collaborators Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet 2005, 366:1267-1278. Cholesterol Treatment Trialists' Collaborators.
2. Bellosta S, Paoletti R, Corsini A. Safety of statins: focus on clinical pharmacokinetics and drug interactions. Circulation 2004, 109(23 Suppl 1):III50-III57.
3. Colhoun HM, Betteridge DJ, Durrington PN, Hitman GA, Neil HA, Livingstone SJ, Thomason MJ, Mackness MI, Charlton-Menys V, Fuller JH, . CARDS Investigators Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. Lancet 2004, 364:685-696. 10.1016/S0140-6736(04)16895-5, 15325833, CARDS Investigators.
4. Sever PS, Dahlöf B, Poulter NR, Wedel H, Beevers G, Caulfield M, Collins R, Kjeldsen SE, Kristinsson A, McInnes GT, Mehlsen J, Nieminen M, O'Brien E, Ostergren J, . ASCOT Investigators Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial - Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. Lancet 2003, 361:1149-1158. 10.1016/S0140-6736(03)12948-0, 12686036, ASCOT Investigators.
5. Arnaud C, Braunersreuther V, Mach F. Toward immunomodulatory and anti-inflammatory properties of statins. Trends Cardiovasc Med 2005, 15:202-206. 10.1016/j.tcm.2005.07.002, 16182129.
6. Kwak BR, Mulhaupt F, Mach F. Atherosclerosis: anti-inflammatory and immunomodulatory activities of statins. Autoimmun Rev 2003, 2:332-338. 10.1016/S1568-9972(03)00049-1, 14550874.
7. Mausner-Fainberg K, Luboshits G, Mor A, Maysel-Auslender S, Rubinstein A, Keren G, George J. The effect of HMG-CoA reductase inhibitors on naturally occurring CD4+CD25+ T cells. Atherosclerosis 2008, 197:829-839. 10.1016/j.atherosclerosis.2007.07.031, 17826781.
8. Ridker PM, Danielson E, Fonseca FA, Genest J, Gotto AM, Kastelein JJ, Koenig W, Libby P, Lorenzatti AJ, Macfadyen JG, Nordestgaard BG, Shepherd J, Willerson JT, Glynn RJ, . JUPITER Trial Study Group Reduction in C-reactive protein and LDL cholesterol and cardiovascular event rates after initiation of rosuvastatin: a prospective study of the JUPITER trial. Lancet 2009, 373:1175-1182. 10.1016/S0140-6736(09)60447-5, 19329177, JUPITER Trial Study Group.
9. de Jong HJ, Klungel OH, van Dijk L, Vandebriel RJ, Leufkens HG, van der Laan J, Tervaert JW, van Loveren H. Use of statins is associated with an increased risk of rheumatoid arthritis. Ann Rheum Dis 2012, 71:648-654. 10.1136/ard.2011.155622, 21979000.
10. de Jong HJ, Tervaert JW, Saldi SR, Vandebriel RJ, Souverein PC, Meyboom RH, van Loveren H, Klungel OH. Association between statin use and lupus-like syndrome using spontaneous reports. Semin Arthritis Rheum 2011, 41:373-381. 10.1016/j.semarthrit.2011.06.002, 21868063.
11. Moulis G, Béné J, Sommet A, Sailler L, Lapeyre-Mestre M, Montastruc JL, . Regional Pharmacovigilance Centers FA Statin-induced lupus: a case/non-case study in a nationwide pharmacovigilance database. Lupus 2012, Regional Pharmacovigilance Centers FA.
12. Bevaart L, Vervoordeldonk MJ, Tak PP. Collagen-induced arthritis in mice. Methods Mol Biol 2010, 602:181-192. 10.1007/978-1-60761-058-8_11, 20012399.
13. Ho PP, Higgins JP, Kidd BA, Tomooka B, Digennaro C, Lee LY, de Vegvar HE, Steinman L, Robinson WH. Tolerizing DNA vaccines for autoimmune arthritis. Autoimmunity 2006, 39:675-682. 10.1080/08916930601061603, 17178564.
14. Yamagata T, Kinoshita K, Nozaki Y, Sugiyama M, Ikoma S, Funauchi M. Effects of pravastatin in murine collagen-induced arthritis. Rheumatol Int 2007, 27:631-639. 10.1007/s00296-006-0270-9, 17119970.
15. Leung BP, Sattar N, Crilly A, Prach M, McCarey DW, Payne H, Madhok R, Campbell C, Gracie JA, Liew FY, McInnes IB. A novel anti-inflammatory role for simvastatin in inflammatory arthritis. J Immunol 2003, 170:1524-1530.
16. Palmer G, Chobaz V, Talabot-Ayer D, Taylor S, So A, Gabay C, Busso N. Assessment of the efficacy of different statins in murine collagen-induced arthritis. Arthritis Rheum 2004, 50:4051-4059. 10.1002/art.20673, 15593180.
17. Zadelaar S, Kleemann R, Verschuren L, de Vries-Van der Weij J, van der Hoorn J, Princen HM, Kooistra T. Mouse models for atherosclerosis and pharmaceutical modifiers. Arterioscler Thromb Vasc Biol 2007, 27:1706-1721. 10.1161/ATVBAHA.107.142570, 17541027.
18. Maron DJ, Fazio S, Linton MF. Current perspectives on statins. Circulation 2000, 101:207-213.
19. Vandebriel RJ, Gremmer ER, Vermeulen JP, Hellwig SM, Dormans JA, Roholl PJ, Mooi FR. Lung pathology and immediate hypersensitivity in a mouse model after vaccination with pertussis vaccines and challenge with Bordetella pertussis. Vaccine 2007, 25:2346-2360. 10.1016/j.vaccine.2005.09.062, 17224216.
20. Slob W. Dose-response modeling of continuous endpoints. Toxicol Sci 2002, 66:298-312. 10.1093/toxsci/66.2.298, 11896297.
21. PROAST. , http://www.proast.nl
22. Appel MJ, Bouman HGM, Pieters MN, Slob W. Evaluation of the applicability of the Benchmark approach to existing toxicological data. RIVM Report 601930 001 , http://www.rivm.nl/bibliotheek/rapporten/601930001.html
23. Nielen MM, van Schaardenburg D, Reesink HW, van de Stadt RJ, van der Horst-Bruinsma IE, de Koning MH, Habibuw MR, Vandenbroucke JP, Dijkmans BA. Specific autoantibodies precede the symptoms of rheumatoid arthritis: a study of serial measurements in blood donors. Arthritis Rheum 2004, 50:380-386. 10.1002/art.20018, 14872479.
24. Murphy CA, Langrish CL, Chen Y, Blumenschein W, McClanahan T, Kastelein RA, Sedgwick JD, Cua DJ. Divergent pro- and antiinflammatory roles for IL-23 and IL-12 in joint autoimmune inflammation. J Exp Med 2003, 198:1951-1957. 10.1084/jem.20030896, 2194162, 14662908.
25. Lubberts E, Joosten LA, Oppers B, van den Bersselaar L, Coenen-de Roo CJ, Kolls JK, Schwarzenberger P, van de Loo FA, van den Berg WB. IL-1-independent role of IL-17 in synovial inflammation and joint destruction during collagen-induced arthritis. J Immunol 2001, 167:1004-1013.
26. Nakae S, Nambu A, Sudo K, Iwakura Y. Suppression of immune induction of collagen-induced arthritis in IL-17-deficient mice. J Immunol 2003, 171:6173-6177.
27. Lubberts E, Koenders MI, Oppers-Walgreen B, van den Bersselaar L, Coenen-de Roo CJ, Joosten LA, van den Berg WB. Treatment with a neutralizing anti-murine interleukin-17 antibody after the onset of collagen-induced arthritis reduces joint inflammation, cartilage destruction, and bone erosion. Arthritis Rheum 2004, 50:650-659. 10.1002/art.20001, 14872510.
28. Schurgers E, Billiau A, Matthys P. Collagen-induced arthritis as an animal model for rheumatoid arthritis: focus on interferon-α. J Interferon Cytokine Res 2011, 31:917-926. 10.1089/jir.2011.0056, 21905879.
29. Youssef S, Stüve O, Patarroyo JC, Ruiz PJ, Radosevich JL, Hur EM, Bravo M, Mitchell DJ, Sobel RA, Steinman L, Zamvil SS. The HMG-CoA reductase inhibitor, atorvastatin, promotes a Th2 bias and reverses paralysis in central nervous system autoimmune disease. Nature 2002, 420:78-84. 10.1038/nature01158, 12422218.
30. Manoury-Schwartz B, Chiocchia G, Bessis N, Abehsira-Amar O, Batteux F, Muller S, Huang S, Boissier MC, Fournier C. High susceptibility to collagen-induced arthritis in mice lacking IFN-gamma receptors. J Immunol 1997, 158:5501-5506.
31. Vermeire K, Heremans H, Vandeputte M, Huang S, Billiau A, Matthys P. Accelerated collagen-induced arthritis in IFN-gamma receptor-deficient mice. J Immunol 1997, 158:5507-5513.
32. Coward WR, Marei A, Yang A, Vasa-Nicotera MM, Chow SC. Statin-induced proinflammatory response in mitogen-activated peripheral blood mononuclear cells through the activation of caspase-1 and IL-18 secretion in monocytes. J Immunol 2006, 176:5284-5292.
33. Wannamaker W, Davies R, Namchuk M, Pollard J, Ford P, Ku G, Decker C, Charifson P, Weber P, Germann UA, Kuida K, Randle JC. (S)-1-((S)-2-{[1-(4-amino-3-chloro-phenyl)-methanoyl]-amino}-3,3-dimethyl-butanoyl)-pyrrolidine-2-carboxylic acid ((2R,3S)-2-ethoxy-5-oxo-tetrahydro-furan-3-yl)-amide (VX-765), an orally available selective interleukin (IL)-converting enzyme/caspase-1 inhibitor, exhibits potent anti-inflammatory activities by inhibiting the release of IL-1β and IL-18. Pharmacol Exp Ther 2007, 321:509-516.
34. Hom JT, Bendele AM, Carlson DG. In vivo administration with IL-1 accelerates the development of collagen-induced arthritis in mice. J Immunol 1988, 141:834-841.
35. Joosten LA, Helsen MM, van de Loo FA, van den Berg WB. Anticytokine treatment of established type II collagen-induced arthritis in DBA/1 mice. A comparative study using anti-TNF alpha, anti-IL-1 alpha/beta, and IL-1Ra. Arthritis Rheum 1996, 39:797-809. 10.1002/art.1780390513, 8639177.
36. Gracie JA, Forsey RJ, Chan WL, Gilmour A, Leung BP, Greer MR, Kennedy K, Carter R, Wei XQ, Xu D, Field M, Foulis A, Liew FY, McInnes IB. A proinflammatory role for IL-18 in rheumatoid arthritis. J Clin Invest 1999, 104:1393-1401. 10.1172/JCI7317, 409841, 10562301.
37. Leung BP, McInnes IB, Esfandiari E, Wei XQ, Liew FY. Combined effects of IL-12 and IL-18 on the induction of collagen-induced arthritis. J Immunol 2000, 164:6495-6502.
38. Wei XQ, Leung BP, Arthur HM, McInnes IB, Liew FY. Reduced incidence and severity of collagen-induced arthritis in mice lacking IL-18. J Immunol 2001, 166:517-521.
39. Bendele A. Animal models of rheumatoid arthritis. J Musculoskelet Neuronal Interact 2001, 1:377-385.
40. Brand DD. Rodent models of rheumatoid arthritis. Comp Med 2005, 55:114-122.
41. Hegen M, Keith JC, Collins M, Nickerson-Nutter CL. Utility of animal models for identification of potential therapeutics for rheumatoid arthritis. Ann Rheum Dis 2008, 67:1505-1515.
42. Kollias G, Papadaki P, Apparailly F, Vervoordeldonk MJ, Holmdahl R, Baumans V, Desaintes C, Di Santo J, Distler J, Garside P, Hegen M, Huizinga TW, Jüngel A, Klareskog L, McInnes I, Ragoussis I, Schett G, Hart B, Tak PP, Toes R, van den Berg W, Wurst W, Gay S. Animal models for arthritis: innovative tools for prevention and treatment. Ann Rheum Dis 2011, 70:1357-1362. 10.1136/ard.2010.148551, 21628308.